ID   PKHM1_HUMAN             Reviewed;        1056 AA.
AC   Q9Y4G2; Q6P2R5; Q8TEL9; Q9NPP5; Q9NYA0;
DT   13-NOV-2007, integrated into UniProtKB/Swiss-Prot.
DT   13-NOV-2007, sequence version 3.
DT   28-JUN-2023, entry version 166.
DE   RecName: Full=Pleckstrin homology domain-containing family M member 1 {ECO:0000305};
DE            Short=PH domain-containing family M member 1;
DE   AltName: Full=162 kDa adapter protein;
DE            Short=AP162;
GN   Name=PLEKHM1 {ECO:0000312|HGNC:HGNC:29017}; Synonyms=KIAA0356;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 82-1056, TISSUE SPECIFICITY, FUNCTION, AND
RP   INTERACTION WITH SIALYL-LEX POSITIVE MUCIN.
RC   TISSUE=Colon carcinoma;
RX   PubMed=12820725; DOI=10.1023/a:1022256610674;
RA   Hartel-Schenk S., Gratchev A., Hanski M.-L., Ogorek D., Trendelenburg G.,
RA   Hummel M., Hoepfner M., Scheruebl H., Zeitz M., Hanski C.;
RT   "Novel adapter protein AP162 connects a sialyl-Le(x)-positive mucin with an
RT   apoptotic signal transduction pathway.";
RL   Glycoconj. J. 18:915-923(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 425-1056.
RC   TISSUE=Spleen;
RA   Jikuya H., Takano J., Nomura N., Kikuno R., Nagase T., Ohara O.;
RT   "The nucleotide sequence of a long cDNA clone isolated from human spleen.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 528-832.
RG   The European IMAGE consortium;
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   FUNCTION, INTERACTION WITH RAB7, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   CYS-1021; CYS-1024; HIS-1029 AND CYS-1032.
RX   PubMed=20943950; DOI=10.1091/mbc.e10-06-0495;
RA   Tabata K., Matsunaga K., Sakane A., Sasaki T., Noda T., Yoshimori T.;
RT   "Rubicon and PLEKHM1 negatively regulate the endocytic/autophagic pathway
RT   via a novel Rab7-binding domain.";
RL   Mol. Biol. Cell 21:4162-4172(2010).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-432, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH RAB7A; VPS41 AND
RP   S.TYPHIMURIUM SIFA, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   720-LYS--LEU-722; GLU-729 AND ARG-769.
RX   PubMed=25500191; DOI=10.1016/j.chom.2014.11.011;
RA   McEwan D.G., Richter B., Claudi B., Wigge C., Wild P., Farhan H.,
RA   McGourty K., Coxon F.P., Franz-Wachtel M., Perdu B., Akutsu M.,
RA   Habermann A., Kirchof A., Helfrich M.H., Odgren P.R., Van Hul W.,
RA   Frangakis A.S., Rajalingam K., Macek B., Holden D.W., Bumann D., Dikic I.;
RT   "PLEKHM1 regulates Salmonella-containing vacuole biogenesis and
RT   infection.";
RL   Cell Host Microbe 17:58-71(2015).
RN   [10]
RP   FUNCTION, INTERACTION WITH VPS41; VPS11; VPS39; GABARAP; GABARAPL;
RP   GABARAPL2; MAP1LC3A; MAP1LC3B AND MAP1LC3C, SUBUNIT, SUBCELLULAR LOCATION,
RP   AND DOMAIN.
RX   PubMed=25498145; DOI=10.1016/j.molcel.2014.11.006;
RA   McEwan D.G., Popovic D., Gubas A., Terawaki S., Suzuki H., Stadel D.,
RA   Coxon F.P., Miranda de Stegmann D., Bhogaraju S., Maddi K., Kirchof A.,
RA   Gatti E., Helfrich M.H., Wakatsuki S., Behrends C., Pierre P., Dikic I.;
RT   "PLEKHM1 regulates autophagosome-lysosome fusion through HOPS complex and
RT   LC3/GABARAP proteins.";
RL   Mol. Cell 57:39-54(2015).
RN   [11]
RP   FUNCTION, INTERACTION WITH ARL8A; ARL8B; RAB7A; VPS41; VPS11; VPS18 AND
RP   VPS33A, SUBCELLULAR LOCATION, AND MUTAGENESIS OF HIS-60; HIS-63 AND
RP   119-ARG--ARG-123.
RX   PubMed=28325809; DOI=10.1083/jcb.201607085;
RA   Marwaha R., Arya S.B., Jagga D., Kaur H., Tuli A., Sharma M.;
RT   "The Rab7 effector PLEKHM1 binds Arl8b to promote cargo traffic to
RT   lysosomes.";
RL   J. Cell Biol. 216:1051-1070(2017).
RN   [12]
RP   INVOLVEMENT IN OPTB6.
RX   PubMed=17404618; DOI=10.1172/jci30328;
RA   van Wesenbeeck L., Odgren P.R., Coxon F.P., Frattini A., Moens P.,
RA   Perdu B., MacKay C.A., Van Hul E., Timmermanns J.-P., Vanhoenacker F.,
RA   Jacobs R., Peruzzi B., Teti A., Helfrich M.H., Rogers M.J., Villa A.,
RA   Van Hul W.;
RT   "Involvement of PLEKHM1 in osteoclastic vesicular transport and
RT   osteopetrosis in incisors absent rats and humans.";
RL   J. Clin. Invest. 117:919-930(2007).
RN   [13]
RP   INVOLVEMENT IN OPTA3, AND VARIANT OPTA3 CYS-714.
RX   PubMed=17997709; DOI=10.1359/jbmr.071107;
RA   Del Fattore A., Fornari R., Van Wesenbeeck L., de Freitas F.,
RA   Timmermans J.P., Peruzzi B., Cappariello A., Rucci N., Spera G.,
RA   Helfrich M.H., Van Hul W., Migliaccio S., Teti A.;
RT   "A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin
RT   homolog domain containing family M (with run domain) member 1 (PLEKHM1),
RT   impairs vesicular acidification and increases TRACP secretion in
RT   osteoclasts.";
RL   J. Bone Miner. Res. 23:380-391(2008).
RN   [14]
RP   INVOLVEMENT IN OPTA3.
RX   PubMed=27291868; DOI=10.1002/jbmr.2885;
RA   Bo T., Yan F., Guo J., Lin X., Zhang H., Guan Q., Wang H., Fang L., Gao L.,
RA   Zhao J., Xu C.;
RT   "Characterization of a Relatively Malignant Form of Osteopetrosis Caused by
RT   a Novel Mutation in the PLEKHM1 Gene.";
RL   J. Bone Miner. Res. 31:1979-1987(2016).
CC   -!- FUNCTION: Acts as a multivalent adapter protein that regulates Rab7-
CC       dependent and HOPS complex-dependent fusion events in the endolysosomal
CC       system and couples autophagic and the endocytic trafficking pathways.
CC       Acts as a dual effector of RAB7A and ARL8B that simultaneously binds
CC       these GTPases, bringing about clustering and fusion of late endosomes
CC       and lysosomes (PubMed:25498145, PubMed:28325809). Required for late
CC       stages of endolysosomal maturation, facilitating both endocytosis-
CC       mediated degradation of growth factor receptors and autophagosome
CC       clearance. Interaction with Arl8b is a crucial factor in the terminal
CC       maturation of autophagosomes and to mediate autophagosome-lysosome
CC       fusion (PubMed:25498145). Positively regulates lysosome peripheral
CC       distribution and ruffled border formation in osteoclasts (By
CC       similarity). May be involved in negative regulation of endocytic
CC       transport from early endosome to late endosome/lysosome implicating its
CC       association with Rab7 (PubMed:20943950). May have a role in sialyl-lex-
CC       mediated transduction of apoptotic signals (PubMed:12820725). Involved
CC       in bone resorption (By similarity). {ECO:0000250|UniProtKB:Q5PQS0,
CC       ECO:0000250|UniProtKB:Q7TSI1, ECO:0000269|PubMed:12820725,
CC       ECO:0000269|PubMed:20943950, ECO:0000269|PubMed:25498145,
CC       ECO:0000269|PubMed:28325809}.
CC   -!- FUNCTION: (Microbial infection) In case of infection contributes to
CC       Salmonella typhimurium pathogenesis by supporting the integrity of the
CC       Salmonella-containing vacuole (SCV) probably in concert with the HOPS
CC       complex and Rab7. {ECO:0000269|PubMed:25500191}.
CC   -!- SUBUNIT: Interacts (via N- and C-terminus) with RAB7A (GTP-bound form)
CC       (PubMed:20943950, PubMed:25500191, PubMed:28325809). Simultaneously
CC       interacts with RAB7A and ARL8B; bringing about clustering and fusion of
CC       late endosomes and lysosomes (PubMed:28325809). Interacts (via RUN
CC       domain) with ARL8B (GTP-bound form); the interaction is required for
CC       PLEKHM1 localization to lysosomes and for ARL8B function in delivery
CC       and degradation of endocytic and autophagic cargo in lysosomes
CC       (PubMed:28325809). PLEKHM1 and PLEKHM2 compete for interaction with
CC       ARL8B (PubMed:28325809). Interacts with ARL8A; the interaction is
CC       weaker than with ARL8B (PubMed:28325809). Interacts with VPS41, VPS11,
CC       VPS18, VPS33A and VPS39; indicative for an association with the HOPS
CC       complex; the interactions with, at least, VPS41, VPS11, VPS18 and
CC       VPS33A require ARL8B (PubMed:25500191, PubMed:25498145,
CC       PubMed:28325809). Interacts with GABARAP, GABARAPL, GABARAPL2,
CC       MAP1LC3A, MAP1LC3B and MAP1LC3C (PubMed:25498145). Interacts with
CC       PAFAH1B (By similarity). Interacts (via N- and C-terminus) with NDEL1
CC       (By similarity). Interacts (via C-terminus) with MAP3K7 (By
CC       similarity). Interacts (via N- and C-terminus) with FAM98A (By
CC       similarity). Interacts (via C-terminus) with DEF8; this interaction is
CC       weak but increased in a RAB7A-dependent manner (By similarity). In
CC       colon carcinoma and breast carcinoma cells, it interacts with sialyl-
CC       lex-positive protein (PubMed:12820725). {ECO:0000250|UniProtKB:Q7TSI1,
CC       ECO:0000269|PubMed:12820725, ECO:0000269|PubMed:20943950,
CC       ECO:0000269|PubMed:25498145, ECO:0000269|PubMed:28325809}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Salmonella typhimurium
CC       sifA. {ECO:0000269|PubMed:25500191}.
CC   -!- INTERACTION:
CC       Q9Y4G2; Q96BM9: ARL8A; NbExp=2; IntAct=EBI-473814, EBI-4401082;
CC       Q9Y4G2; Q9NVJ2: ARL8B; NbExp=20; IntAct=EBI-473814, EBI-718376;
CC       Q9Y4G2; O95166: GABARAP; NbExp=2; IntAct=EBI-473814, EBI-712001;
CC       Q9Y4G2; P42345: MTOR; NbExp=6; IntAct=EBI-473814, EBI-359260;
CC       Q9Y4G2; P51149: RAB7A; NbExp=11; IntAct=EBI-473814, EBI-1056089;
CC       Q9Y4G2; Q96JC1: VPS39; NbExp=5; IntAct=EBI-473814, EBI-1050197;
CC       Q9Y4G2; P49754: VPS41; NbExp=9; IntAct=EBI-473814, EBI-2130459;
CC       Q9Y4G2; P18067: RAB7A; Xeno; NbExp=9; IntAct=EBI-473814, EBI-7991906;
CC       Q9Y4G2; A0A0D6GID3: sifA; Xeno; NbExp=5; IntAct=EBI-473814, EBI-30861778;
CC   -!- SUBCELLULAR LOCATION: Autolysosome membrane
CC       {ECO:0000269|PubMed:25498145}. Endosome membrane
CC       {ECO:0000269|PubMed:20943950}. Late endosome membrane
CC       {ECO:0000269|PubMed:28325809}. Lysosome membrane
CC       {ECO:0000269|PubMed:25498145, ECO:0000269|PubMed:25500191,
CC       ECO:0000269|PubMed:28325809}. Note=In case of infection colocalizes
CC       with Salmonella typhimurium sifA in proximity of Salmonella-containing
CC       vacuole (SCV) (PubMed:25500191). {ECO:0000269|PubMed:25498145,
CC       ECO:0000269|PubMed:25500191}.
CC   -!- TISSUE SPECIFICITY: Expressed in placenta, liver, prostate, thymus,
CC       spleen, ovary, colon, colon carcinoma and peripheral blood lymphocytes
CC       (PBL). Weakly expressed in brain, lung, kidney, and testis. No
CC       expression in heart, skeletal muscle, pancreas and small intestine.
CC       Predominantly expressed in the breast carcinoma cell line MCF-7.
CC       {ECO:0000269|PubMed:12820725, ECO:0000269|PubMed:9205841}.
CC   -!- DOMAIN: The LIR (LC3-interacting region) motif mediates the interaction
CC       with ATG8 family proteins GABARAP, GABARAPL, GABARAPL2, and LC3A/B/C.
CC       {ECO:0000269|PubMed:25498145}.
CC   -!- DISEASE: Osteopetrosis, autosomal recessive 6 (OPTB6) [MIM:611497]: A
CC       rare genetic disease characterized by abnormally dense bone, due to
CC       defective resorption of immature bone. Osteopetrosis occurs in two
CC       forms: a severe autosomal recessive form occurring in utero, infancy,
CC       or childhood, and a benign autosomal dominant form occurring in
CC       adolescence or adulthood. Recessive osteopetrosis commonly manifests in
CC       early infancy with macrocephaly, feeding difficulties, evolving
CC       blindness and deafness, bone marrow failure, severe anemia, and
CC       hepatosplenomegaly. Deafness and blindness are generally thought to
CC       represent effects of pressure on nerves. {ECO:0000269|PubMed:17404618}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Osteopetrosis, autosomal dominant 3 (OPTA3) [MIM:618107]: A
CC       form of osteopetrosis, a rare genetic disease characterized by
CC       abnormally dense bone, due to defective resorption of immature bone.
CC       Osteopetrosis occurs in two forms: a severe autosomal recessive form
CC       occurring in utero, infancy, or childhood, and an autosomal dominant
CC       form occurring in adolescence or adulthood. OPTA3 is characterized by
CC       typical features of osteopetrosis such as fractures after minor trauma,
CC       early tooth loss, anemia, hepatosplenomegaly, and a generalized
CC       increase in bone mineral density. Some patients exhibit localized
CC       osteosclerosis and generalized osteopenia.
CC       {ECO:0000269|PubMed:17997709, ECO:0000269|PubMed:27291868}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Sialyl-lex is a carcinoma associated antigen.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA20813.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAB91652.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB002354; BAA20813.2; ALT_INIT; mRNA.
DR   EMBL; BC064361; AAH64361.1; -; mRNA.
DR   EMBL; AJ002220; CAB91652.1; ALT_INIT; mRNA.
DR   EMBL; AK074103; BAB84929.1; -; mRNA.
DR   EMBL; AL389948; CAB97526.1; -; mRNA.
DR   CCDS; CCDS32671.1; -.
DR   RefSeq; NP_055613.1; NM_014798.2.
DR   RefSeq; XP_006722264.1; XM_006722201.3.
DR   RefSeq; XP_011523825.1; XM_011525523.2.
DR   RefSeq; XP_011523826.1; XM_011525524.1.
DR   RefSeq; XP_016880940.1; XM_017025451.1.
DR   RefSeq; XP_016880942.1; XM_017025453.1.
DR   PDB; 5DPR; X-ray; 2.50 A; A/B/C/D=627-638.
DR   PDB; 5DPS; X-ray; 2.00 A; A/B/C=627-638.
DR   PDB; 5DPT; X-ray; 2.90 A; A/B=627-638.
DR   PDB; 5DPW; X-ray; 2.19 A; B/D/F/H/J/L/N/P=629-642.
DR   PDBsum; 5DPR; -.
DR   PDBsum; 5DPS; -.
DR   PDBsum; 5DPT; -.
DR   PDBsum; 5DPW; -.
DR   AlphaFoldDB; Q9Y4G2; -.
DR   SMR; Q9Y4G2; -.
DR   BioGRID; 115178; 54.
DR   IntAct; Q9Y4G2; 50.
DR   MINT; Q9Y4G2; -.
DR   STRING; 9606.ENSP00000389913; -.
DR   GlyCosmos; Q9Y4G2; 2 sites, 1 glycan.
DR   GlyGen; Q9Y4G2; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q9Y4G2; -.
DR   PhosphoSitePlus; Q9Y4G2; -.
DR   BioMuta; PLEKHM1; -.
DR   DMDM; 160419247; -.
DR   EPD; Q9Y4G2; -.
DR   jPOST; Q9Y4G2; -.
DR   MassIVE; Q9Y4G2; -.
DR   MaxQB; Q9Y4G2; -.
DR   PaxDb; Q9Y4G2; -.
DR   PeptideAtlas; Q9Y4G2; -.
DR   ProteomicsDB; 86202; -.
DR   Antibodypedia; 30012; 148 antibodies from 27 providers.
DR   DNASU; 9842; -.
DR   Ensembl; ENST00000430334.8; ENSP00000389913.3; ENSG00000225190.12.
DR   Ensembl; ENST00000446609.7; ENSP00000394344.3; ENSG00000225190.12.
DR   Ensembl; ENST00000613787.3; ENSP00000479066.1; ENSG00000277111.3.
DR   Ensembl; ENST00000617688.2; ENSP00000483820.1; ENSG00000276358.2.
DR   GeneID; 9842; -.
DR   KEGG; hsa:9842; -.
DR   MANE-Select; ENST00000430334.8; ENSP00000389913.3; NM_014798.3; NP_055613.1.
DR   UCSC; uc002ija.4; human.
DR   AGR; HGNC:29017; -.
DR   CTD; 9842; -.
DR   DisGeNET; 9842; -.
DR   GeneCards; PLEKHM1; -.
DR   HGNC; HGNC:29017; PLEKHM1.
DR   HPA; ENSG00000225190; Tissue enhanced (esophagus).
DR   MalaCards; PLEKHM1; -.
DR   MIM; 611466; gene.
DR   MIM; 611497; phenotype.
DR   MIM; 618107; phenotype.
DR   neXtProt; NX_Q9Y4G2; -.
DR   OpenTargets; ENSG00000225190; -.
DR   Orphanet; 210110; Intermediate osteopetrosis.
DR   PharmGKB; PA134906881; -.
DR   VEuPathDB; HostDB:ENSG00000225190; -.
DR   eggNOG; KOG1829; Eukaryota.
DR   GeneTree; ENSGT00940000155111; -.
DR   HOGENOM; CLU_011318_0_0_1; -.
DR   InParanoid; Q9Y4G2; -.
DR   OMA; HVLNCDL; -.
DR   OrthoDB; 126314at2759; -.
DR   PhylomeDB; Q9Y4G2; -.
DR   TreeFam; TF317067; -.
DR   PathwayCommons; Q9Y4G2; -.
DR   SignaLink; Q9Y4G2; -.
DR   BioGRID-ORCS; 9842; 58 hits in 1153 CRISPR screens.
DR   ChiTaRS; PLEKHM1; human.
DR   GeneWiki; PLEKHM1; -.
DR   GenomeRNAi; 9842; -.
DR   Pharos; Q9Y4G2; Tbio.
DR   PRO; PR:Q9Y4G2; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q9Y4G2; protein.
DR   Bgee; ENSG00000225190; Expressed in lower esophagus mucosa and 93 other tissues.
DR   ExpressionAtlas; Q9Y4G2; baseline and differential.
DR   Genevisible; Q9Y4G2; HS.
DR   GO; GO:0044754; C:autolysosome; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0061909; P:autophagosome-lysosome fusion; IMP:UniProtKB.
DR   GO; GO:1902774; P:late endosome to lysosome transport; IMP:UniProtKB.
DR   GO; GO:0032418; P:lysosome localization; IDA:UniProtKB.
DR   GO; GO:0045780; P:positive regulation of bone resorption; ISS:UniProtKB.
DR   GO; GO:1900029; P:positive regulation of ruffle assembly; ISS:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   CDD; cd13321; PH_PLEKHM1; 1.
DR   CDD; cd17679; RUN_PLEKHM1; 1.
DR   Gene3D; 1.20.58.900; -; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR042827; PLEKHM1_PH.
DR   InterPro; IPR025258; RH_dom.
DR   InterPro; IPR004012; Run_dom.
DR   InterPro; IPR037213; Run_dom_sf.
DR   InterPro; IPR047326; RUN_PLEKHM1.
DR   PANTHER; PTHR12326; PLECKSTRIN HOMOLOGY DOMAIN CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR12326:SF5; PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING FAMILY M MEMBER 1; 1.
DR   Pfam; PF02759; RUN; 1.
DR   Pfam; PF13901; zf-RING_9; 1.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM01175; DUF4206; 1.
DR   SMART; SM00233; PH; 2.
DR   SMART; SM00593; RUN; 1.
DR   SUPFAM; SSF50729; PH domain-like; 2.
DR   SUPFAM; SSF140741; RUN domain-like; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50826; RUN; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Autophagy; Cytoplasmic vesicle; Disease variant; Endosome;
KW   Lysosome; Membrane; Metal-binding; Osteopetrosis; Phosphoprotein;
KW   Protein transport; Reference proteome; Repeat; Transport; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..1056
FT                   /note="Pleckstrin homology domain-containing family M
FT                   member 1"
FT                   /id="PRO_0000309335"
FT   DOMAIN          41..183
FT                   /note="RUN"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00178"
FT   DOMAIN          534..625
FT                   /note="PH 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          683..777
FT                   /note="PH 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   ZN_FING         986..1040
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          215..245
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          277..303
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          360..422
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          451..483
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          654..1056
FT                   /note="Interaction with RAB7A"
FT                   /evidence="ECO:0000269|PubMed:25500191"
FT   MOTIF           632..638
FT                   /note="LIR"
FT                   /evidence="ECO:0000305"
FT   COMPBIAS        218..238
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        385..412
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         219
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7TSI1"
FT   MOD_RES         432
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         435
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7TSI1"
FT   MOD_RES         490
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7TSI1"
FT   VARIANT         377
FT                   /note="R -> H (in dbSNP:rs1859059)"
FT                   /id="VAR_036932"
FT   VARIANT         714
FT                   /note="R -> C (in OPTA3; unknown pathological significance;
FT                   dbSNP:rs559224144)"
FT                   /evidence="ECO:0000269|PubMed:17997709"
FT                   /id="VAR_081102"
FT   MUTAGEN         60
FT                   /note="H->A: Strongly reduces interaction with ARL8B. No
FT                   effect on interaction with RAB7A. No effect on late
FT                   endosome and lysosome clustering. Loss of interaction with
FT                   ARL8B as well as late endosome and lysosome clustering;
FT                   when associated with 119-A--A-123."
FT                   /evidence="ECO:0000269|PubMed:28325809"
FT   MUTAGEN         63
FT                   /note="H->A: No effect on interaction with ARL8B. No effect
FT                   on interaction with RAB7A."
FT                   /evidence="ECO:0000269|PubMed:28325809"
FT   MUTAGEN         119..123
FT                   /note="RAWLR->AAWLA: Reduces interaction with ARL8B. No
FT                   effect on interaction with RAB7A. Loss of interaction with
FT                   ARL8B as well as late endosome and lysosome clustering;
FT                   when associated with A-60."
FT                   /evidence="ECO:0000269|PubMed:28325809"
FT   MUTAGEN         720..722
FT                   /note="Missing: Disrupts interaction with RAB7A."
FT                   /evidence="ECO:0000269|PubMed:25500191"
FT   MUTAGEN         729
FT                   /note="E->A: Disrupts interaction with RAB7A."
FT                   /evidence="ECO:0000269|PubMed:25500191"
FT   MUTAGEN         769
FT                   /note="R->A: Disrupts interaction with RAB7A."
FT                   /evidence="ECO:0000269|PubMed:25500191"
FT   MUTAGEN         1021
FT                   /note="C->G: Disrupts interaction with Rab7 and no
FT                   localization to endososmal membranes; when associated with
FT                   G-1024, L-1029 and G-1032."
FT                   /evidence="ECO:0000269|PubMed:20943950"
FT   MUTAGEN         1024
FT                   /note="C->G: Disrupts interaction with Rab7 and no
FT                   localization to endososmal membranes; when associated with
FT                   G-1021, L-1029 and G-1032."
FT                   /evidence="ECO:0000269|PubMed:20943950"
FT   MUTAGEN         1029
FT                   /note="H->L: Disrupts interaction with Rab7 and no
FT                   localization to endososmal membranes; when associated with
FT                   G-1021, G-1024 and G-1032."
FT                   /evidence="ECO:0000269|PubMed:20943950"
FT   MUTAGEN         1032
FT                   /note="C->G: Disrupts interaction with Rab7and no
FT                   localization to endososmal membranes; when associated with
FT                   G-1021, G-1024 and L-1029."
FT                   /evidence="ECO:0000269|PubMed:20943950"
FT   CONFLICT        429..436
FT                   /note="VVSSPTSP -> GLRPVSAR (in Ref. 4; BAB84929)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        817
FT                   /note="A -> G (in Ref. 4; BAB84929)"
FT                   /evidence="ECO:0000305"
FT   STRAND          635..637
FT                   /evidence="ECO:0007829|PDB:5DPW"
SQ   SEQUENCE   1056 AA;  117443 MW;  24004093CFA89079 CRC64;
     MLSVVENGLD PQAAIPVIKK KLVGSVKALQ KQYVSLDTVV TSEDGDANTM CSALEAVFIH
     GLHAKHIRAE AGGKRKKSAH QKPLPQPVFW PLLKAVTHKH IISELEHLTF VNTDVGRCRA
     WLRLALNDGL MECYLKLLLQ EQARLHEYYQ PTALLRDAEE GEFLLSFLQG LTSLSFELSY
     KSAILNEWTL TPLALSGLCP LSELDPLSTS GAELQRKESL DSISHSSGSE DIEVHHSGHK
     IRRNQKLTAS SLSLDTASSS QLSCSLNSDS CLLQENGSKS PDHCEEPMSC DSDLGTANAE
     DSDRSLQEVL LEFSKAQVNS VPTNGLSQET EIPTPQASLS LHGLNTSTYL HCEAPAEPLP
     AQAASGTQDG VHVQEPRPQA PSPLDLQQPV ESTSGQQPSS TVSETAREVG QGNGLQKAQA
     HDGAGLKLVV SSPTSPKNKS WISEDDFYRP SREQPLESAS DHPIASYRGT PGSRPGLHRH
     FSQEPRKNCS LGALDQACVP SPGRRQAQAA PSQGHKSFRV VHRRQMGLSN PFRGLMKLGT
     VERRGAMGIW KELFCELSPL EFRLYLSNEE HTCVENCSLL RCESVGPAHS DGRFELVFSG
     KKLALRASSQ DEAEDWLDRV REALQKVRPQ QEDEWVNVQY PDQPEEPPEA PQGCLSPSDL
     LSEPAALQGT QFDWSSAQVP EPDAIKESLL YLYMDRTWMP YIFSLSLEAL KCFRIRNNEK
     MLSDSHGVET IRDILPDTSL GGPSFFKIIT AKAVLKLQAG NAEEAALWRD LVRKVLASYL
     ETAEEAVTLG GSLDENCQEV LKFATRENGF LLQYLVAIPM EKGLDSQGCF CAGCSRQIGF
     SFVRPKLCAF SGLYYCDICH QDDASVIPAR IIHNWDLTKR PICRQALKFL TQIRAQPLIN
     LQMVNASLYE HVERMHLIGR RREQLKLLGD YLGLCRSGAL KELSKRLNHR NYLLESPHRF
     SVADLQQIAD GVYEGFLKAL IEFASQHVYH CDLCTQRGFI CQICQHHDII FPFEFDTTVR
     CAECKTVFHQ SCQAVVKKGC PRCARRRKYQ EQNIFA
//
